NCT02584478 2023-11-08
AL3818
Advenchen Laboratories, LLC
Phase 3 Unknown
Clinical Trials
11 trialsNCT05976932 2023-08-04
Circulating Tumor DNA Monitoring in Platinum-resistant Ovarian Cancer
Fudan University
Unknown
NCT00326456 2023-03-27
MITO-2: A Study Comparing 2 Chemotherapy Regimens (Carboplatin/Liposomal Doxorubicin vs Carboplatin/Paclitaxel) in Patients With Ovarian Cancer
National Cancer Institute, Naples
Phase 3 Unknown
NCT01802749 2023-03-24
MITO16MANGO2b
National Cancer Institute, Naples
Phase 3 Unknown
NCT03794778 2022-07-18
Evaluation of PLD Combined With Carboplatin Versus Paclitaxel Plus Carboplatin in the First-line Treatment of Epithelial Ovarian Cancer
Women's Hospital School Of Medicine Zhejiang University
Phase 4 Unknown
NCT04679064 2021-08-27
NItCHE-MITO33
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase 3 Unknown
NCT02822157 2021-01-29
CLIO
Universitaire Ziekenhuizen KU Leuven
Phase 2 Unknown
NCT03539328 2018-05-29
MITO27
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 2 Unknown
NCT03335241 2017-11-13
Study of Fludarabine With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer
Sun Yat-sen University
Phase 2 Unknown
NCT01715168 2015-01-15
A Crossover Bioequivalence Study of Intravenously Administered ATI0918 and DOXIL/CAELYX in Patients With Ovarian Cancer
Azaya Therapeutics, Inc.
Phase 1 Unknown
NCT01388621 2013-08-20
PROVE
WiSP Wissenschaftlicher Service Pharma GmbH
Phase 2 Unknown